ZA973843B - Treatment of asthma with TNFR-lg. - Google Patents

Treatment of asthma with TNFR-lg.

Info

Publication number
ZA973843B
ZA973843B ZA9703843A ZA973843A ZA973843B ZA 973843 B ZA973843 B ZA 973843B ZA 9703843 A ZA9703843 A ZA 9703843A ZA 973843 A ZA973843 A ZA 973843A ZA 973843 B ZA973843 B ZA 973843B
Authority
ZA
South Africa
Prior art keywords
tnfr
asthma
treatment
Prior art date
Application number
ZA9703843A
Other languages
English (en)
Inventor
Louis Martin Renzetti
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA973843B publication Critical patent/ZA973843B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA9703843A 1996-05-08 1997-05-05 Treatment of asthma with TNFR-lg. ZA973843B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1684296P 1996-05-08 1996-05-08

Publications (1)

Publication Number Publication Date
ZA973843B true ZA973843B (en) 1997-11-10

Family

ID=21779275

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9703843A ZA973843B (en) 1996-05-08 1997-05-05 Treatment of asthma with TNFR-lg.

Country Status (15)

Country Link
EP (1) EP0910413A2 (xx)
JP (1) JP2000510113A (xx)
KR (1) KR20000010825A (xx)
CN (1) CN1233189A (xx)
AR (1) AR007020A1 (xx)
AU (1) AU725408B2 (xx)
BR (1) BR9708928A (xx)
CA (1) CA2253557A1 (xx)
CO (1) CO4820397A1 (xx)
HR (1) HRP970224A2 (xx)
MA (1) MA24169A1 (xx)
PE (1) PE70698A1 (xx)
TR (1) TR199802238T2 (xx)
WO (1) WO1997041895A2 (xx)
ZA (1) ZA973843B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1044267A2 (en) * 1997-12-29 2000-10-18 Regeneron Pharmaceuticals, Inc. Novel nucleic acid and polypeptide with homology to the tnf-receptors
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
JP4980048B2 (ja) * 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム 腫瘍壊死因子結合タンパク質の液体製剤
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20090071652A (ko) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132471A3 (de) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
WO1994006476A1 (en) * 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5684222A (en) * 1993-01-22 1997-11-04 Ontario Cancer Institute Mutant mouse having a disrupted TNFRp55
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
JPH09508140A (ja) * 1994-07-22 1997-08-19 エフ・ホフマン−ラ ロシュ アーゲー キメラｔｎｆ結合タンパク質を含有する医薬組成物
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
AU2776497A (en) 1997-11-26
HRP970224A2 (en) 1998-04-30
AU725408B2 (en) 2000-10-12
MA24169A1 (fr) 1997-12-31
PE70698A1 (es) 1998-11-18
CN1233189A (zh) 1999-10-27
BR9708928A (pt) 2000-05-09
WO1997041895A2 (en) 1997-11-13
EP0910413A2 (en) 1999-04-28
KR20000010825A (ko) 2000-02-25
JP2000510113A (ja) 2000-08-08
CA2253557A1 (en) 1997-11-13
CO4820397A1 (es) 1999-07-28
AR007020A1 (es) 1999-10-13
WO1997041895A3 (en) 1998-03-12
TR199802238T2 (xx) 1999-02-22

Similar Documents

Publication Publication Date Title
GB9411080D0 (en) Treatment
ZA979731B (en) Treatment of asthma.
ZA97986B (en) Treatment of liquors.
GB9619492D0 (en) Novel treatment
ZA978640B (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis.
GB9410512D0 (en) Novel treatment
ZA973843B (en) Treatment of asthma with TNFR-lg.
ZA976350B (en) Treatment of liquid.
GB9615767D0 (en) Novel treatment
GR3032700T3 (en) Air treatment
ZA977867B (en) Method of treatment.
GB9608657D0 (en) Novel treatment
ZA973380B (en) Treatment of washwater.
GB9726223D0 (en) The treatment of materials
ZA951226B (en) The treatment of gaseous substances
GB9625795D0 (en) Novel treatment
GB9612752D0 (en) Novel treatment
ZA9711116B (en) The treatment of materials.
HU9600619D0 (en) Treatment with onion-oil
GB9617762D0 (en) Treatment
AUPO019296A0 (en) Treatment of asthma
GB9614740D0 (en) Novel treatment
GB9616410D0 (en) Novel treatment
GB9604046D0 (en) Novel treatment
GB9610986D0 (en) Novel treatment